Pharmacokinetics of gestodene and ethinyl estradiol after oral administration of a monophasic contraceptive
U Täuber, W Kuhnz, M Hümpel - American journal of obstetrics and …, 1990 - Elsevier
The pharmacokinetic and protein-binding properties of gestodene and ethinyl estradiol have
been investigated after single and multiple dosing in several studies in 83 healthy, young …
been investigated after single and multiple dosing in several studies in 83 healthy, young …
Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein …
W Kuhnz, A Baumann, T Staks, L Dibbelt, R Knuppen… - Contraception, 1993 - Elsevier
The pharmacokinetics of gestodene (GEST) and ethinylestradiol (EE 2) were determined in
14 healthy women (age 18 to 32 years) during a treatment period of three months with a new …
14 healthy women (age 18 to 32 years) during a treatment period of three months with a new …
Pharmacokinetics and protein binding of gestodene under treatment with a low-dose combination oral contraceptive for three months.
L Dibbelt, R Knuppen, W Kuhnz, G Jütting - Arzneimittel-forschung, 1992 - europepmc.org
The serum concentrations of gestodene (CAS 60282-87-3) as well as the binding of this
progestin to serum proteins were studied in 40 women who took a low-dose oral …
progestin to serum proteins were studied in 40 women who took a low-dose oral …
Pharmacokinetics and pharmacodynamics of oral contraceptive steroids: factors influencing steroid metabolism
C Jung-Hoffmann, H Kuhl - American journal of obstetrics and gynecology, 1990 - Elsevier
The time-dependent alterations in the serum concentrations of ethinyl estradiol, gestodene,
and 3-keto-desogestrel during treatment with 30 µg of ethinyl estradiol+ 75 µg of gestodene …
and 3-keto-desogestrel during treatment with 30 µg of ethinyl estradiol+ 75 µg of gestodene …
The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel
M Orme, DJ Back, S Ward, S Green - Contraception, 1991 - Elsevier
Single doses of ethynylestradiol (30 μg) were given alone and in combination with either
gestodene (75 μg) or desogestrel (150 μg) to 10 healthy female volunteers. The doses of …
gestodene (75 μg) or desogestrel (150 μg) to 10 healthy female volunteers. The doses of …
Pharmacokinetics and serum protein binding of gestodene and 3-keto-desogestrel in women after single oral administration of two different contraceptive formulations.
W Kuhnz, B Schütt, J Power, DJ Back - Arzneimittel-forschung, 1992 - europepmc.org
Two low-dose oral contraceptives, both containing the same dose of ethinyl estradiol (EE2,
CAS 57-63-6) but different progestins--gestodene (CAS 60282-87-3) and desogestrel (CAS …
CAS 57-63-6) but different progestins--gestodene (CAS 60282-87-3) and desogestrel (CAS …
Clinical acceptability of monophasic gestodene
B Düsterberg, K Brill - American journal of obstetrics and gynecology, 1990 - Elsevier
The monophasic low-dose contraceptive containing 30 μg of ethinyl estradiol and 75 μg of
gestodene has been tested in numerous clinical studies to determine contraceptive …
gestodene has been tested in numerous clinical studies to determine contraceptive …
Single and multiple administration of a new triphasic oral contraceptive to women: Pharmacokinetics of ethin l estradiol and free and total testosterone levels in serum
W Kuhnz, D Sostarek, C Gansau, T Louton… - American journal of …, 1991 - Elsevier
Ethinyl estradiol is part of almost every combined oral contraceptive, and its pharmacokinetic
characteristics have been thoroughly investigated in numerous studies. However, little is …
characteristics have been thoroughly investigated in numerous studies. However, little is …
Serum distribution of two contraceptive progestins: 3-ketodesogestrel and gestodene
GL Hammond, WP Bocchinfuso, M Orava, CL Smith… - Contraception, 1994 - Elsevier
A cross-over study of two oral contraceptive formulations, containing 30 μg ethinylestradiol
in combination with 150 μg desogestrel (Marvelon®) or 75 μg gestodene (Femovan®), has …
in combination with 150 μg desogestrel (Marvelon®) or 75 μg gestodene (Femovan®), has …
Pharmacokinetics of desogestrel
HD McClamrock, EY Adashi - American journal of obstetrics and …, 1993 - Elsevier
A synthetic form of desogestrel, a gonane progestin, was developed because desogestrel's
enhanced selectivity eliminates adverse, androgen-dependent, metabolic effects at …
enhanced selectivity eliminates adverse, androgen-dependent, metabolic effects at …